Literature DB >> 17664396

Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation.

Ryotaro Takahashi1, Toru Asai, Hisashi Murakami, Ryuichiro Murakami, Michitaka Tsuzuki, Yasushi Numaguchi, Hideo Matsui, Toyoaki Murohara, Kenji Okumura.   

Abstract

Primary systemic carnitine deficiency is an autosomal recessive disorder caused by a decreased renal reabsorption of carnitine because of mutations of the carnitine transporter OCTN2 gene, and hypertrophic cardiomyopathy is a common clinical feature of homozygotes. Although heterozygotes for OCTN2 mutations are generally healthy with normal cardiac performance, heterozygotes may be at risk for cardiomyopathy in the presence of additional risk factors, such as hypertension. To test this hypothesis, we investigated the effects of surgically induced pressure overload on the hearts of heterozygous mutants of a murine model of OCTN2 mutation, juvenile visceral steatosis mouse (jvs/+). Eleven-week-old jvs/+ mice and age-matched wild-type mice were used. At baseline, there were no differences in physical characteristics between wild-type and jvs/+ mice. However, plasma and myocardial total carnitine levels in jvs/+ mice were lower than in wild-type mice. Both wild-type and jvs/+ mice were subjected to ascending aortic constriction with or without 1% l-carnitine supplementation for 4 weeks. At 4 weeks after ascending aortic constriction, jvs/+ mice showed an exaggeration of cardiac hypertrophy and pulmonary congestion, further increased gene expression of atrial natriuretic peptide in the left ventricles, further deterioration of left ventricular fractional shortening, reduced myocardial phosphocreatine:adenosine triphosphate ratio, and increased mortality compared with wild-type mice; l-carnitine supplementation prevented these changes in jvs/+ mice subjected to ascending aortic constriction. In conclusion, cardiomyopathy and heart failure with energy depletion may be induced by pressure overload in heterozygotes for OCTN2 mutations and could be prevented by l-carnitine supplementation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664396     DOI: 10.1161/HYPERTENSIONAHA.107.088609

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

1.  Slc22a5 haploinsufficiency does not aggravate the phenotype of the long-chain acyl-CoA dehydrogenase KO mouse.

Authors:  Pablo Ranea-Robles; Chunli Yu; Naomi van Vlies; Frédéric M Vaz; Sander M Houten
Journal:  J Inherit Metab Dis       Date:  2019-12-23       Impact factor: 4.982

2.  Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.

Authors:  Markus Grube; Sabine Ameling; Michel Noutsias; Kathleen Köck; Ivonne Triebel; Karina Bonitz; Konrad Meissner; Gabriele Jedlitschky; Lars R Herda; Markus Reinthaler; Maria Rohde; Wolfgang Hoffmann; Uwe Kühl; Heinz-Peter Schultheiss; Uwe Völker; Stephan B Felix; Karin Klingel; Reinhard Kandolf; Heyo K Kroemer
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 3.  Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis.

Authors:  Wei Wu; Ankur V Dnyanmote; Sanjay K Nigam
Journal:  Mol Pharmacol       Date:  2011-02-11       Impact factor: 4.436

4.  Cardiomyopathy and carnitine deficiency.

Authors:  Cristina Amat di San Filippo; Matthew R G Taylor; Luisa Mestroni; Lorenzo D Botto; Nicola Longo
Journal:  Mol Genet Metab       Date:  2008-03-11       Impact factor: 4.797

Review 5.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

6.  Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha) in alcoholic cardiomyopathy.

Authors:  Ling Jing; Li-jun Zhou; Wei-min Li; Feng-min Zhang; Lin Yuan; Shuang Li; Jian Song; Ying Sang
Journal:  Med Sci Monit       Date:  2011-01

Review 7.  Primary carnitine deficiency and cardiomyopathy.

Authors:  Lijun Fu; Meirong Huang; Shubao Chen
Journal:  Korean Circ J       Date:  2013-12       Impact factor: 3.243

8.  Association between ACR1 gene product expression and cardiomyopathy in children.

Authors:  Yan Wang; Ling Niu; Xiuhua He; Ying Xue; Nan Ling; Zhenzhou Wang; Xinjiang An
Journal:  Exp Ther Med       Date:  2016-07-05       Impact factor: 2.447

9.  Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency.

Authors:  Jan Rasmussen; Allan M Lund; Lotte Risom; Flemming Wibrand; Hannes Gislason; Olav W Nielsen; Lars Køber; Morten Duno
Journal:  Mol Genet Metab Rep       Date:  2014-05-22

10.  Experimental modelling of cardiac pressure overload hypertrophy: Modified technique for precise, reproducible, safe and easy aortic arch banding-debanding in mice.

Authors:  David Merino; Aritz Gil; Jenny Gómez; Luis Ruiz; Miguel Llano; Raquel García; María A Hurlé; J Francisco Nistal
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.